Gene · 6121
Papers3,325
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 3,325
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Linking Mitochondrial Gene Dysregulation to Immune Cell Shifts in Retinitis Pigmentosa. | Mol Neurobiol | 2025 | 41286208 | PubTator, text mining | PubMed |
| Mild RPE65-Associated Inherited Retinal Dystrophies: A Multimodal Clinical and Genetic Evaluation. | Transl Vis Sci Technol | 2025 | 41251530 | PubTator, text mining | PubMed |
Generation and characterization of three human induced pluripotent stem cell lines (UGENTi005, UGENTi006 and UGENTi007) from patients with autosomal dominant adult-onset maculopathy due to RPE65 variant c.1555G>A, p.(E519K). | Stem Cell Res | 2025 | 41197496 | PubTator, text mining | PubMed |
| Targeting Angiogenesis and Visual Cycle in Age-Related Macular Degeneration: The Role of Stem Cells and Vinpocetine. | Cureus | 2025 | 41194821 | PubTator, text mining | PubMed |
| Location and Identity of Photoreceptors Contributing to the Full-Field Stimulus Test (FST). | Invest Ophthalmol Vis Sci | 2025 | 41147951 | PubTator, text mining | PubMed |
| Clinical and pharmacovigilance safety evaluation of LUXTURNA® (voretigene neparvovec-rzyl). | Cutan Ocul Toxicol | 2025 | 41140124 | PubTator, text mining | PubMed |
| One down but many more to go: the state of gene therapy for inherited retinal disease. | Regen Med | 2025 | 41054259 | PubTator, text mining | PubMed |
| Higher Throughput Assays for Understanding the Pathogenicity of Variants of Unknown Significance in the RPE65 Gene. | Invest Ophthalmol Vis Sci | 2025 | 41051147 | PubTator, text mining | PubMed |
| Coping behavior toward occupational health risks among construction workers: determinant identification using the COM-B model and data mining analysis. | Front Public Health | 2025 | 41018795 | PubTator, text mining | PubMed |
| Evolving Real-World Data and Evidence Use for New Drugs and Regenerative Medical Products Approvals in Japan-An Analysis of the 6-Year Trend. | Clin Pharmacol Ther | 2025 | 41017142 | PubTator, text mining | PubMed |
| GUCY2D-Associated Retinopathy: A Comparative Study Between Humans and German Spitz Dogs. | Vet Sci | 2025 | 41012804 | PubTator, text mining | PubMed |
| Minigene Splice Assays Allow Pathogenicity Reclassification of RPE65 Variants of Uncertain Significance. | Genes (Basel) | 2025 | 41009968 | PubTator, text mining | PubMed |
| Ophthalmic drug discovery and development using artificial intelligence and digital health technologies. | NPJ Digit Med | 2025 | 40998989 | PubTator, text mining | PubMed |
| Prevalence of loss-of-function, gain-of-function and dominant-negative mechanisms across genetic disease phenotypes. | Nat Commun | 2025 | 40998763 | PubTator, text mining | PubMed |
| Characterisation of vitreous derived small extracellular vesicles in diabetic retinopathy. | Exp Eye Res | 2025 | 40992588 | PubTator, text mining | PubMed |
| RPE65 Variant p.(E519K) Causes a Novel Dominant Adult-Onset Maculopathy in 83 Affected Individuals. | Invest Ophthalmol Vis Sci | 2025 | 40985799 | PubTator, text mining | PubMed |
| From Pathophysiology to Innovative Therapies in Eye Diseases: A Brief Overview. | Int J Mol Sci | 2025 | 40943417 | PubTator, text mining | PubMed |
| Efficacy and Safety of Voretigene Neparvovec in RPE65-Retinopathy: Results of a Phase III Trial in Japan. | Ophthalmol Sci | 2025 | 40910102 | PubTator, text mining | PubMed |
| Evaluating the long-term efficacy of umbilical cord-derived mesenchymal stem cell therapy in retinitis pigmentosa: findings from a 1-to-4-year follow-up. | Stem Cells Transl Med | 2025 | 40905668 | PubTator, text mining | PubMed |
| Cystoid Macular Edema in Non-Syndromic Retinitis Pigmentosa: Associations With Causative Genes in a Large Cohort. | Invest Ophthalmol Vis Sci | 2025 | 40900079 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6121/papers?page=4